Mazyar Shadman, MD, MPH, discusses data from the phase 1/1b BGB-11417-101 trial of sonrotoclax plus zanubrutinib in frontline CLL/SLL.
Back
Parsing Early Data for Sonrotoclax/Zanubrutinib in Treatment-Naive CLL
Mazyar Shadman, MD, MPH, and colleagues shared phase 1 data for sonrotoclax plus zanubrutinib in treatment-naive chronic lymphocytic leukemia.
Parsing Early Data for Sonrotoclax/Zanubrutinib in Treatment-Naive CLL
Episodes
All
All
Sonrotoclax plus zanubrutinib drove durable remissions across IGHV-mutated and del(17p)/TP53 CLL subgroups in an updated phase 1/1b analysis.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
3
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
4
EGFR PACC Mutations Define a Distinct NSCLC Subclass With Growing Treatment Options
5